Barclays PLC cut shares of Trevena, Inc. (NASDAQ:TRVN) from an overweight rating to an equal weight rating in a research report report published on Monday. They currently have $2.50 price target on the biopharmaceutical company’s stock, down from their previous price target of $15.00.

A number of other equities research analysts have also issued reports on the company. Oppenheimer Holdings, Inc. set a $5.00 price target on Trevena and gave the company a buy rating in a research report on Thursday, October 12th. HC Wainwright reduced their price target on Trevena from $8.00 to $7.00 and set a buy rating on the stock in a research report on Thursday, October 12th. Zacks Investment Research lowered Trevena from a buy rating to a hold rating in a research report on Friday, August 25th. Finally, Cowen and Company reaffirmed a buy rating and issued a $10.00 price target on shares of Trevena in a research report on Friday, August 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $9.63.

Trevena (TRVN) opened at 2.13 on Monday. The stock’s market cap is $127.15 million. The firm has a 50-day moving average price of $2.47 and a 200 day moving average price of $2.72. Trevena has a 1-year low of $1.84 and a 1-year high of $8.00.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35). On average, equities research analysts anticipate that Trevena will post ($1.40) EPS for the current fiscal year.

WARNING: “Trevena, Inc. (TRVN) Downgraded to Equal Weight at Barclays PLC” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/10/17/trevena-inc-trvn-downgraded-to-equal-weight-at-barclays-plc.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TRVN. Wells Fargo & Company MN increased its holdings in shares of Trevena by 38.4% in the 1st quarter. Wells Fargo & Company MN now owns 222,349 shares of the biopharmaceutical company’s stock valued at $817,000 after acquiring an additional 61,650 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Trevena by 40.4% in the 1st quarter. Bank of New York Mellon Corp now owns 231,553 shares of the biopharmaceutical company’s stock valued at $851,000 after acquiring an additional 66,577 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Trevena by 81.0% in the 1st quarter. SG Americas Securities LLC now owns 35,926 shares of the biopharmaceutical company’s stock valued at $132,000 after acquiring an additional 16,079 shares during the last quarter. American International Group Inc. increased its holdings in shares of Trevena by 7.1% in the 1st quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 1,816 shares during the last quarter. Finally, FMR LLC increased its holdings in shares of Trevena by 4.5% in the 1st quarter. FMR LLC now owns 7,037,804 shares of the biopharmaceutical company’s stock valued at $25,828,000 after acquiring an additional 304,256 shares during the last quarter. Institutional investors and hedge funds own 60.09% of the company’s stock.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.